Cargando…

Switching to tenofovir disoproxil fumarate in entecavir-treated chronic hepatitis B patients: A pilot randomized controlled study

Although hepatitis B surface antigen (HBsAg) removal is considered the goal of chronic hepatitis B treatment, it can rarely be achieved with nucleos(t)ide analogues (NAs). It has been reported that tenofovir disoproxil fumarate (TDF) is superior in reducing HBsAg compared with entecavir (ETV) in tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inoue, Jun, Akahane, Takehiro, Kobayashi, Tomoo, Obara, Noriyuki, Umetsu, Teruyuki, Kakazu, Eiji, Ninomiya, Masashi, Iwata, Tomoaki, Sano, Akitoshi, Tsuruoka, Mio, Sato, Kosuke, Masamune, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739848/ https://www.ncbi.nlm.nih.gov/pubmed/33335726 http://dx.doi.org/10.3892/br.2020.1396

Ejemplares similares

Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study
por: Sato, Kosuke, et al.
Publicado: (2022)

Methotrexate-associated Lymphoproliferative Disorder in the Liver Resembling Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
por: Tsuruoka, Mio, et al.
Publicado: (2020)

Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate
por: Ha, Yeonjung, et al.
Publicado: (2020)

Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis
por: Ma, Xuefeng, et al.
Publicado: (2021)

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir
por: Suzuki, Fumitaka, et al.
Publicado: (2014)

Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B
por: Liao, Xingmei, et al.
Publicado: (2023)

Hepatitis B Virus Reactivation with Discontinuation of Nucleoside Analogue in Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation
por: Tsuruoka, Mio, et al.
Publicado: (2021)

Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021)

Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir
por: Lim, Jung Hyun, et al.
Publicado: (2021)

Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis
por: Liu, Zekun, et al.
Publicado: (2023)

Non-Achievement of Alanine Aminotransferase Normalization Associated with the Risk of Hepatocellular Carcinoma during Nucleos(t)ide Analogue Therapies: A Multicenter Retrospective Study
por: Inoue, Jun, et al.
Publicado: (2022)

Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
por: Cui, Guangying, et al.
Publicado: (2015)

Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B
por: Kim, Young Min, et al.
Publicado: (2018)

Tenofovir-disoproxil-fumarate: Elevation in ALP: case report
Publicado: (2020)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
por: Yim, Hyung Joon, et al.
Publicado: (2022)

Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
por: Li, Juan, et al.
Publicado: (2021)

Acute-onset Autoimmune Hepatitis in a Young Woman with Type 1 Diabetes Mellitus
por: Takai, Satoshi, et al.
Publicado: (2018)

Inhibitory effect of silibinin on hepatitis B virus entry
por: Umetsu, Teruyuki, et al.
Publicado: (2018)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
por: Funderburg, Nicholas T., et al.
Publicado: (2016)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Michienzi, Sarah M, et al.
Publicado: (2021)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate‐Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
por: Bukkems, Vera E., et al.
Publicado: (2020)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
por: Hill, Andrew, et al.
Publicado: (2018)

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate
por: Huhn, Gregory D, et al.
Publicado: (2019)

Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate
por: Eke, Ahizechukwu C
Publicado: (2022)

Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study
por: Suzuki, Fumitaka, et al.
Publicado: (2021)

Inverse Propensity Score-Weighted Analysis of Entecavir and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B: A Large-Scale Multicenter Study
por: Kim, Jihye, et al.
Publicado: (2023)

Osteopenia in a young man associated with the use of tenofovir disoproxil fumarate
por: Li, Chunmei, et al.
Publicado: (2022)

96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients
por: Liu, Zhihong, et al.
Publicado: (2023)

Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis
por: Huang, Ze-Hong, et al.
Publicado: (2022)

Efficacy and safety of tenofovir disoproxil fumarate versus entecavir in the treatment of acute-on-chronic liver failure with hepatitis B: a systematic review and meta-analysis
por: Wang, Neng, et al.
Publicado: (2023)

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate
por: Hermansson, Linn, et al.
Publicado: (2019)

Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study
por: Abe, Kensuke, et al.
Publicado: (2021)

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
por: Suzuki, Kazuharu, et al.
Publicado: (2022)

Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
por: Thimm, Matthew A., et al.
Publicado: (2022)

3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
por: Hou, Jinlin, et al.
Publicado: (2021)

Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation
por: Cheng, Chih-Hsien, et al.
Publicado: (2023)

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023)

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
por: He, Jingjing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eb48lhj6usjtv884igor480edr